Patent ID: 8287872
Filing Date: 2012-10-16
Classification: A61K,A61P,C07K

Abstract:
1. A method of decreasing PAR-2 activity in a subject with an inflammatory condition of the skin, joints, gastrointestinal system and/or airway comprising administering to the subject a pharmaceutical comprising an antigen binding protein that binds to full-length proteinase activated receptor-2 (PAR-2) and binds to a lesser extent to cleaved PAR-2, thereby binding a loop 1 peptide of PAR-2 consisting of amino acids 29 through 46 of SEQ ID NO:2 which includes a proteolytic cleavage site between R36 and S37 upstream of the cleavage site, wherein the antigen binding protein antagonizes the proteolytic activation of PAR-2 with an IC50 of 60 nM or less in a fluorometric imaging plate reader (FLIPR) assay using HCT-116 cells.